PCSK1 and myeloid sarcoma: The RIPK1 increase has been observed in the microglia of AD, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) mouse models, and the RIPK1 inhibitor necrostatin-1 (Nec-1) treatment reduced proinflammatory cytokine expression [16].